Table 3.
Clinical outcomes in COVID-19 pneumonia and community-acquired pneumonia (CAP) patients.
| COVID-19 pneumonia group | CAP group | p-Value | |
|---|---|---|---|
| Critical care management | |||
| Total | 19/72 (26%) | 12/72 (17%) | 0.16 |
| PE positive group | 9/17 (53%) | 2/5 (40%) | 0.61 |
| PE negative group | 10/55 (18%) | 10/67 (15%) | 0.63 |
| Death | |||
| Total | 14/72 (19%) | 8/72 (11%) | 0.17 |
| PE positive group | 4/17 (24%) | 1/5 (20%) | 0.87 |
| PE negative group | 10/55 (18%) | 7/67 (10%) | 0.22 |
| Level of PE in confirmed cases | |||
| Central | 3/17 (17.7%) | 0/5 (0%) | 0.31 |
| Lobar | 9/17 (52.9%) | 3/5 (60%) | 0.78 |
| Segmental | 5/17 (29.4%) | 2/5 (40%) | 0.66 |
| Subsegmental | 0/17 (0%) | 0/17 (0%) | NS |
Data are n (%).
PE, pulmonary embolism; NS indicates non-significant.